Last year was a record year for venture capital investment in digital health startups – the industry improve $29.1 billion out of 729 deals, with an average deal size of $39.9 million.According to a recent report, this market boom is over, but the digital health investment space is not collapsing in any way Report from rock healthy. It just cools down after a hot year.
In the first half of the year, digital health startups raised $10.3 billion in 329 deals, with an average deal size of $31.2 million. That puts the industry on track for $21 billion in revenue in 2022, about $8 billion less than the total raised last year.
Venture capital funding for healthcare companies is still ahead of 2020, despite the slower pace of investment in the first half of the year compared to 2021, according to Venture Capital CEO David Blumberg year level. Bloomberg Capital, pointed out in the interview. Investment firms are certainly still pouring money into digital health, and these startups are still developing technologies that are attractive to the health system, he said.
“As health systems continue to generate vast amounts of data, funding is flowing to startups that are deploying artificial intelligence and machine learning solutions to harness this data for prevention, diagnosis and treatment,” he said.
Health systems also continue to adopt technology from startups focused on telemedicine and remote patient monitoring. This trend has been reinforced by the pandemic, Blumberg noted, “accelerating our society’s migration to a more virtualized model of living and working.”
When choosing which healthcare companies to invest in, Blumberg Capital only considers startups that can demonstrate they use data to improve clinical outcomes and reduce costs. Blumberg said companies consider six T’s when evaluating companies: theme, team, terrain, technology, traction and terms. All companies funded by Blumberg Capital must be able to explain these thoroughly.
iron and theater Here are two examples of companies that have entered Blumberg Capital’s portfolio over the past two years. The former uses algorithms to automatically and inexpensively scan hospital radiology diagnoses as a “second opinion” for quality assurance, error reduction and training purposes. The latter sells an AI-powered surgical tool that can extract and annotate key moments from real-world surgeries to help train surgeons for future surgeries.
Blumberg Capital is an early-stage investment firm, so Blumberg said it will always be able to choose from a steady stream of healthcare startups promising new ways to use data to benefit patients and healthcare professionals. The investment space for late-stage startups looks a little different. Late-stage digital health startups are using this market opportunity to rethink valuations, reduce expenses and design their go-to-market strategies, the report said.
After a large Series A or B deal, some of these companies may need to adjust their expectations, which could mean selling shares at a lower price than the previous round. But that’s not the case for all digital health startups that experienced rapid growth in their early years — Rock Health’s report noted that some of the companies in its portfolio have substantially exceeded pre-pandemic financial projections.
One thing is for sure, 2022 will not see as many startups hitting the public markets as it did last year. So far this year, no startups have gone public, while 23 exited in 2021.
Photo: Orilaki, Getty Images
